Crossmark

Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing?

Crossref DOI link: https://doi.org/10.1186/s12916-018-1149-9

Published Online: 2018-08-24

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sanyal, Arun J.
License Information

Text and Data Mining valid from 2018-08-24
More Information

Article History

Received: 24 July 2018

Accepted: 6 August 2018

First Online: 24 August 2018

Competing interests

: Dr. Sanyal is President of Sanyal Biotechnology and has stock options in Genfit. He has served as a consultant to AbVie, Astra Zeneca, Nitto Denko, Nimbus, Salix, Tobira, Takeda, Fibrogen, Lilly, Zafgen, Novartis, Pfizer, Immuron, Exhalenz, and Genfit. He has been an unpaid consultant for Intercept, Echosens, Immuron, Amarin, Ardelyx, Fractyl, Syntlogic, Nordic Bioscience, and Bristol Myers Squibb. His institution has received grant support from Gilead, Salix, Tobira, Intercept, Merck, Astra Zeneca, and Novartis. He is also a consultant to Novo Nordisk, Alnylam, Servier, Bird Rock, Tern and have stock options in Galmed.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.